Moxalactam (LY127935; 6059-S) is a new beta-lactam antibiotic. We propose tentative zone standards for agar diffusion susceptibility tests with 30-,ug strains with minimal inhibitory concentrations of 8 ,ug/ml from strains requiring <2 ,ug/ml for inhibition, because the regression line became parabolic at concentrations of 2 pg/ml and below. However, the disk tests were satisfactory for categorizing isolates into the above-described susceptible, moderately susceptible (intermediate), and resistant categories.
Moxalactam (LY127935; 6059-S) is a new beta-lactam antibiotic. We propose tentative zone standards for agar diffusion susceptibility tests with 30-,ug disks. The final selection of minimal inhibitory concentration breakpoints for definition of resistant and susceptible categories must await clinical experience with this drug. Some of the clinical questions to be answered are defined. A moderately susceptible (intermediate) category is proposed for those strains with miniimal inhibitory concentrations of 16 or 32 ,ug/ml (zones 15 to 22 mm in diameter). Strains with miniimal inhibitory concentrations of 264 ,ug/ml are considered resistant, and those with minimal inhibitory concentrations of s8 ,ug/ml are considered susceptible. Tests with 30-,ug disks did not satisfactorily separate strains with minimal inhibitory concentrations of 8 ,ug/ml from strains requiring <2 ,ug/ml for inhibition, because the regression line became parabolic at concentrations of 2 pg/ml and below. However, the disk tests were satisfactory for categorizing isolates into the above-described susceptible, moderately susceptible (intermediate), and resistant categories.
Moxalactam (LY127935; 6059-S) is a new beta-lactam antibacterial agent (a 1-oxa betalactam) with a broad spectrum of activity (3, 4, 4a, 8-10) . The present report summarizes our efforts to establish tentative interpretive zone standards for the Bauer-Kirby disk technique for use during future clinical trials of this drug. Such standards may be subject to change once additional clinical experience is gained with this antibiotic. Some of the specific questions which need to be answered before establishing criteria for interpreting in vitro tests are outlined below.
MATERIALS AND METHODS
Tests with 463 selected bacterial isolates were performed at the Center for Disease Control, Atlanta, Ga., and at the University of California (Davis) Medical Center, Sacramento, Calif., as previously described (2, 5 Class concept. Before we proceeded with the development of a disk diffusion susceptibility testing procedure, it seemed appropriate to determine whether tests with an established cephalosporin could predict susceptibility or resistance to moxalactam. Table 1 summarizes data comparing the activity of moxalactam to the activities of cephalothin, cefamandole, and cefoxitin against the 463 strains included in this study. Microdilution tests with all four antimicrobial agents were categorized as being moderately susceptible or resistant (MIC, 216 ,ug/ml) and susceptible (MIC, _8 uLg/ml). Tests with moxalactam were also categorized into groups with MICs of 264 and c32 ,ug/ml (resistant and susceptible or moderately susceptible). Table 1 lists the number of strains which were susceptible to one drug but not to another drug. Essentially all of the strains which were resistant to moxalactam were also resistant to the cephalosporins. However, a significant number of isolates were not susceptible to cephalothin, cefamandole, or cefoxitin but were susceptible (MIC, _8 ,ug/ml) to moxalactam. An even greater number of strains were moderately susceptible (MIC, 16 or 32 ,jg/ml) to moxalactam but were resistant to the other drugs. Consequently, we concluded that moxalactam represents a class of beta-lac,-tam antimicrobial agents with a uniquely broad spectrum of activity. Tests with the established cephalosporins or cephamycins could not be expected to predict resistance to moxalactam.
Performance of 30-,ug cephalothin disks.
As a control measure, all 463 isolates in this study were tested with 30-Ag cephalothin disks, as well as disks containing 30 jg of moxalactam.
To express mathematically the relationship between MICs and zone diameters, a regression line was calculated by using the least-squares method. MIC correlates of <8 and 232 ,ug/ml were calculated for the current zofle standards of218 mm (susceptible) and c14 mm (resistant), respectively (Fig. 3) . As observed previously (1), the disk test failed to categorize accurately the. few strains with internediate MICs or intermediate zone sizes. However, the majority ofstrains were clearly resistant or susceptible by both methods.
Because Performance of 30-,ig moxalactam disks. Figure 4 shows the correlation between MICs and zone diameters with moxalactam. The error rate-bounded method (6) applied to these data suggested zone size breakpoints of -23 mm for the susceptible category (MIC, s8,ug/ml) and s14 mm for the resistant category (MIC, ,ug/ml). To further confirm these zone size breakpoints, a regression line was calculated by using all data with "on-scale" endpoints (Fig. 4, regres Table 2 for regression formulas. (Fig. 4) suggests that a 14-mm zone should correspond to an MIC of >32 but <64 pg/ml (48 pug/ml).
d The scattergram (Fig. 4) suggests that a 23-mm zone should correspond to an MIC of >8 but <16 pg/ml (12 pg/mI). ' The scattergram (Fig. 4) suggests that a 26-mm zone should correspond to an MIC of >2 but <4 pg/ml (3 pg/mi).
tam, a regression line was calculated for strains with MICs between 64 and 4.0 pg/ml (excluding strains with MICs of s2.0 and >64 pug/ml) (Fig.  4, regression (Fig. 4) . The disk test accurately separates the moderately susceptible pseudomonads and acinetobacters from the susceptible enteric bacilli. Experience in treating infections due to P. aeruginosa orAcinetobacter spp. will be needed to determine the relevance of such in vitro testing results. A sufficient number of moderately susceptible and resistant enteric bacilli were not available to assess the possibility of establishing zone standards that could be used only for tests with the Enterobacteriaceae. Enteric bacilli with zones in the moderately susceptible range should be tested further by a dilution procedure, if they are recovered from a serious infection that is to be treated with moxalactam. In the present series of tests, four enteric bacillus strains gave zones in the intermediate range; three were susceptible (MIC, ci8 ,ig/ml), and one had an MIC of 32 
